France-based Nanobiotix SA is taking steps to conserve cash ahead of results from a Phase 3 trial of its lead radioenhancer NBTXR3 for the treatment of head and neck cancer. The data are expected to be reported in the second half of 2024 which, if positive, would lead to registration and unlock significant milestone payments from the company’s partner Janssen Pharmaceutica NV. Nanobiotix is developing radioenhancers for use with radiotherapy to treat patients with multiple, difficult cancers.
